Organisation paid for research Program year 2021 Source: CMS Open Payments

University Physicians Group Research

Neither a doctor nor a teaching hospital

Research payments

$261,973

91 payments

Through program year 2021, University Physicians Group Research is reported as receiving $261,973 in research payments, across 91 payments.

By program year

3 rows
Year Kind Amount Payments
2021 Research $4,984 11
2020 Research $126,518 69
2019 Research $130,471 11

Breakdown

Who paid Research payments · program years 2019–2021
  1. Sanofi US Services Inc. $244,782 87 payments
  2. Sanofi-Aventis U.S. LLC $17,191 4 payments
Studies the money was for Research payments · program years 2019–2021
  1. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk $113,646 7 payments
  2. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular $42,449 3 payments
  3. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular $38,465 1 payment
  4. A 12-week Randomized, Controlled Trial to Compare TOUJEO and TRESIBA in Terms of Glucose Values in Target Range and Variability During Continuous Glucose Monitoring in Patients With Type 1 Diabete $27,929 50 payments
  5. A randomized, open-label, parallel group real world pragmatic trial to assess the clinical and health outcomes of Toujeo compared to commercially available basal insulins for initiation of therapy in $13,623 2 payments
  6. A 12-week Randomized, Controlled Trial to Compare TOUJEO and TRESIBA in Terms of Glucose Values in Target Range and Variability During Continuous Glucose Monitoring in Patients With Type 1 Diabetes Mellitus $7,641 11 payments
  7. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk $6,574 1 payment
  8. A 12-week Randomized, Controlled Trial to Compare TOUJEO and TRESIBA in Terms of Glucose Values in Target Range and Variability During Continuous Glucose Monitoring in Patients With Type 1 Diabetes Mellitus $4,984 11 payments
  9. A randomized, open-label, parallel group real world pragmatic trial to assess the clinical and health outcomes of Toujeo compared to commercially available basal insulins for initiation of therapy in $3,568 2 payments
  10. A 26-Week Open-label Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Pioglitazone $2,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record